Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: Chemocentryx inc org - Caught on Camera

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Benzinga · Aug 5, 2022

Why ChemoCentryx Shares Are Popping Off

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results.

Benzinga · May 6, 2022

ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer

ChemoCentryx Inc (NASDAQ:CCXI) announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 study of CCX559 at the American Association for Cancer Research (AACR) Annual Meeting 2022. Preclinical characterization demonstrated that CCX559 is a potent inhibitor of PD-L1 that blocks binding to PD-1 and…

Benzinga · Apr 13, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings

Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ:CCXI) following the Q4 results. Analyst Dae Gon Ha says he is "perplexed" by the pronounced weakness on what he views as a positive-launch quarter. Ha tells investors in a research note that 127 patient start forms and 71% conversion rate strike…

Benzinga · Mar 2, 2022

Why ChemoCentryx Shares Are Falling

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower by 12.8% at $25.70 Wednesday morning after the company reported worse-than-expected fourth-quarter EPS and sales results.

Benzinga · Mar 2, 2022

Why ChemoCentryx Shares Are Rising

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis.

Benzinga · Jan 19, 2022

ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis

The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis.

Benzinga · Jan 19, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

Rhythm Pharmaceuticals

ACADIA Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.